Singapore markets close in 6 hours 49 minutes

Straits Times Index
3,308.14
+4.95(+0.15%)
Nikkei
38,660.98
+424.91(+1.11%)
Hang Seng
18,600.20
+21.90(+0.12%)
FTSE 100
8,213.49
+41.34(+0.51%)
Bitcoin USD
63,777.70
-367.70(-0.57%)
CMC Crypto 200
1,373.77
+61.14(+4.66%)

Kodiak Sciences Inc. (KOD)

NasdaqGM - NasdaqGM Real-time price. Currency in USD

Add to watchlist

3.9400

+0.1700

(+4.51%)

At close: 04:00PM EDT

3.9400

0.00

(0.00%)

After hours:

04:16PM EDT

Loading interactive chart…

PR Newswire
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that nine scientific presentations on its clinical and research pipeline programs will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting, being held from May 5 – 9 in Seattle, Washington.
Simply Wall St.
Will Kodiak Sciences (NASDAQ:KOD) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Zacks
Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks
Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.